NCT07077395

Finding Links Between Hot flASHes and CardioVascular Disease

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 40 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?

Conditions

• Menopause-related Hot Flashes

Interventions

Type	Name	Description
DRUG	elinzanetant - reference formulation	elinzanetant 120 mg daily x 12 weeks
DRUG	placebo	placebo daily x 12 weeks

Timeline

• Start date: 2026-04-01
• Primary completion: 2029-10-01
• Completion: 2030-10-01
• First posted: 2025-07-22
• Last updated: 2026-02-12

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study